A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma
| العنوان: | A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma |
|---|---|
| المؤلفون: | Hyung Joon Yim, Jae Youn Cheong, Sang Gyune Kim, Jong Young Choi, Jae Seok Hwang, Kwang Hyub Han, Hyeon U. Im, Ho Jong Chun, Hyun Young Woo, Jun Yong Park, Byoung Kuk Jang, Sung Won Cho, Young Seok Kim, Si Hyun Bae, Seung Kew Yoon, Byung Gil Choi, Soon Ho Um, Yeon Seok Seo |
| المصدر: | Cancer Chemotherapy and Pharmacology. 65:373-382 |
| بيانات النشر: | Springer Science and Business Media LLC, 2009. |
| سنة النشر: | 2009 |
| مصطلحات موضوعية: | Adult, Male, Cancer Research, medicine.medical_specialty, Carcinoma, Hepatocellular, medicine.drug_class, medicine.medical_treatment, Toxicology, Antimetabolite, Gastroenterology, Drug Administration Schedule, Hepatic Artery, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, medicine, Humans, Infusions, Intra-Arterial, Pharmacology (medical), Prospective Studies, Prospective cohort study, Survival rate, Aged, Pharmacology, Chemotherapy, business.industry, Liver Neoplasms, Middle Aged, Prognosis, medicine.disease, Surgery, Survival Rate, Oncology, Fluorouracil, Hepatocellular carcinoma, Female, Cisplatin, Liver cancer, business, medicine.drug |
| الوصف: | Hepatic arterial infusion chemotherapy (HAIC) has been reported to be effective in patients with advanced hepatocellular carcinoma (HCC).In this multicenter, prospective, open-labeled, clinical trial, we randomly assigned 68 patients with advanced HCC to receive either low-dose [n = 32, 5-fluorouracil (FU), 170 mg/m(2) and cisplatin, 7 mg/m(2) on days 1-5] or high-dose HAIC (n = 36, 5-FU, 500 mg/m(2) on days 1-3 and cisplatin, 60 mg/m(2) on day 2) every 4 weeks via an implantable port system.A total of 207 cycles of HAIC was given to the 68 patients. Overall, 6 patients (8.8%) achieved a partial response and 21 patients (30.9%) had stable disease. The objective response rate (CR + PR) was significantly improved in the high-dose group compared to the low-dose group (16.7% vs. 0%, P = 0.024). The median time to disease progression and overall survival were slightly prolonged in the high-dose group compared to the low-dose group (median survival, 193 vs. 153 days; P = 0.108; median time to disease progression, 145 vs. 90 days; P = 0.095). Multivariate analysis showed that tumor response to treatment [P = 0.007, RR 2.27 (95% CI, 1.248-4.132)] was the only factor associated with overall survival. All adverse events were tolerable and successfully managed in both treatment groups.Both HAIC regimens are safe and effective in patients with advanced HCC. High-dose HAIC achieves a better tumor response compared to low-dose HAIC. |
| تدمد: | 1432-0843 0344-5704 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff9430b48a7d1b6f4f2ea379714adcdTest https://doi.org/10.1007/s00280-009-1126-2Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....dff9430b48a7d1b6f4f2ea379714adcd |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14320843 03445704 |
|---|